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Potassium leakageThe present study was aimed at investigating the effect of fullerenol C60(OH)36 on chosen parameters of the
human erythrocyte membrane and the preliminary estimation of the properties of fullerenol as a potential
linking agent transferring the compounds (e.g., anticancer drugs) into themembrane of erythrocytes. The results
obtained in this study conﬁrm the impact of fullerenol on erythrocyte cytoskeletal transmembrane proteins, par-
ticularly on the band 3 protein. The presence of fullerenol in each of the concentrations used prevented degrada-
tion of the band 3 protein. The results show that changes in the morphology of red blood cells caused by high
concentrations of fullerenol (up to 150 mg/L) did not lead to increased red blood cell hemolysis or the leakage
of potassium. Moreover, fullerenol slightly prevented hemolysis and potassium efﬂux. The protective effect of
fullerenol at the concentration of 150 mg/L was 20.3%, and similar results were obtained for the efﬂux of potas-
sium. The study shows that fullerenol slightly changed themorphology of the cells and, therefore, altered the in-
tracellular organization of erythrocytes through the association with cytoskeletal proteins.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Nanotechnology was recognized by the National Cancer Institute as a
discipline that can signiﬁcantly contribute to a breakthrough in cancer
treatment and diagnostics [1]. Many conventional therapies for cancer
are limited by the side effects and properties of drugs, such as rapid re-
moval from the organism or lack of speciﬁcity, which results in unavoid-
able damage of nontarget cells [2,3]. The vast majority of anti-cancer
drugs after administration in an unaltered form show high toxicity to-
wards normal cells as well, damaging primarily hepatocytes and heart
muscle [4–7]. One of the solutions to limit the side effects of anti-cancer
therapies is the utilization of drug carriers, that allow active transport
of the medication directly to the disease-altered tissue [8]. Liposomes,
linear polymers and polymer micelles represent the most popular car-
riers for anti-cancer drugs.
Hopes are also high for the use of new nanocomponents, such as
dendrimers, nanotubes and fullerenes as drug carriers [8–12]. Drug car-
riers should not present toxicity or immunogenicity and should be able
to deliver the agent to the targeted organ. Recent research indicates
that the toxicity of initially promising compounds is too high for medical
use [13–15]. Among other carriers, erythrocytes represent a potentially
attractive and unique carrier for drug delivery [16]. As the naturallar Biophysics, University of
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rights reserved.components of the organism, they are highly biocompatible, biodegrad-
able (easily degradable with no toxic intermediates), and they have
long half-life in the circulation system [17]. They are also easy to obtain
in order to load the cargo. The drug is entrapped into the erythrocytes
or attached to the surface of the cells by using various physical and chem-
ical methods. Surface modiﬁcation of erythrocytes with different com-
pounds, such as glutaraldehyde, antibodies, carbohydrates or biotin is
possible to improve their target speciﬁcity and to increase their circula-
tion half-life. [17–19]. Some of them, such as antibodies and biotin,
show some substrate speciﬁcity; others, like glutaraldehyde, which is a
crosslinking agent, can interact with a variety of erythrocyte membrane
proteins [20,21]. Altogether, these facts indicate the superiority of red
blood cells over synthetic compounds. However, erythrocytes have
some drawbacks that limit their use as drug carriers. In vivo, the most
common problem of using erythrocytes containing cargo is their in-
creased elimination by the reticuloendothelial system (RES). This process
severely limits the use of these cells, as every interactionwith the RES in-
creases their speciﬁcity for off-target organs, namely the spleen, liver and
blood marrow [18,19]. Moreover, the use of crosslinking agents may be
detrimental to the maintenance of erythrocyte integrity and could lead
to accelerated damage of erythrocytes [20–22]. The shortened time of
storage of the loaded erythrocytes is an additional problem [19,21].
Therefore, it is crucial to ﬁnd new and efﬁcient compounds that
would serve as the linkers between erythrocytes and drugs and could
be used to diminish the side effects of chemotherapy. As thesemolecules
serve an anchoring function, they have to possess functional groups
reacting both with the drug and the membrane proteins of the erythro-
cytes. Fullerenols C60(OH)n, water-soluble hydroxyl derivatives of C60,
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and bindboth erythrocytes anddrugs via the hydroxyl groups present on
the surface of their carbon cage. Fullerenols receive a lot of attention in
the ﬁeld of biomedical nanotechnology-related research, primarily due
to their relatively low toxicity in comparison to other nanocompounds
[23,24]. The abundance of hydroxyl groups on the surface provides op-
portunities for creatingmultiple hydrogen bonds between one fullerenol
molecule and various biological compounds as the protein domains of
the plasma membrane or hydrophilic lipid heads. In effect, fullerenols,
by adsorption to components of plasma membranes inﬂuence the con-
formation and function of membranes [14,25]. Our previous work
shows that fullerenol associates primarily with the surface of the plasma
membrane; however, it can also migrate deeper inside the membrane.
Moreover, fullerenol inﬂuences membrane ATPases so that it may mod-
ulate ion transport across membranes [26].
The aim of this work was to assess the inﬂuence of fullerenol
C60(OH)36 on selected parameters of human erythrocyte membranes
and preliminary veriﬁcation of fullerenol as an anchor to erythrocyte
membranes linking drug and plasma membrane.2. Materials and methods
2.1. Chemicals
Fullerene (99.5%) was purchased from SES Research (Houston, TX,
USA) and Amberlite MB20, phenylmethanesulfonyl ﬂuoride (PMSF),
tris(hydroxymethyl)aminomethane (Tris), sodium dodecyl sulfate
(SDS), dithiothreitol (DTT) and bromophenol blue were purchased
from Sigma-Aldrich (Poznan, Poland). Sodium chloride, sodium hy-
droxide, hydrogen peroxide, potassium phosphate monobasic and
Folin–Ciocalteu reagent were purchased from POCh (Gliwice, Poland).
Other chemicals were of the best quality commercially available. All so-
lutions were made with water puriﬁed by the Milli-Q system.2.2. Synthesis of fullerenol
Polihydroxyfullerene (fullerenol) C60(OH)36 was synthesized as de-
scribed earlier [26]. The structure of the obtained hydroxyl derivative of
fullerene C60 was conﬁrmed by elementary analysis, IR spectrophotome-
try (NEXUS FT-IR spectrometer), 1H NMR (Varian Gemini 200 MHz), 13C
NMR (Bruker Avance III 600 MHz) and mass spectroscopy MALDI-TOF
(PerSeptive Biosystems Inc. Voyager Elite).2.3. Preparation of erythrocytes
Blood samples from healthy adult donors were provided by the Re-
gional Blood Bank in Lodz. Erythrocytes were separated from blood
plasma and leukocytes by centrifugation at 400 ×g for 8 min. All proce-
dures were carried out at 4 °C. The buffy coat was removed, erythro-
cytes were washed with phosphate buffered saline (PBS) (pH 7.4) and
resuspended in the same buffer to obtain a hematocrit of 2%.2.4. Preparation of erythrocyte membranes
Erythrocyte membranes were prepared according to the method of
Dodge et al. [27] with some modiﬁcations. Hemolysis was carried out
at 4 °C with 20 volumes of 20 mM Tris–HCl buffer (pH 7.4) containing
1 mM EDTA and 0.5 mM PMSF to inhibit proteases. The membrane
ghosts were washed successively with 20, 10 and 5 mM ice-cold Tris–
HCl buffer (pH 7.4) until the ghosts were free of residual hemoglobin.
Protein concentration in the membrane preparations was determined
by the method of Lowry et al. [28]. The erythrocyte ghosts were kept
frozen at−20 °C and used within a week of preparation.2.5. The interaction of fullerenol with erythrocytes or erythrocyte
plasma membranes
Two percent erythrocyte suspensions in PBS, pH 7.4 or erythro-
cyte plasma membranes (1 mg of membrane protein per mL) were
incubated with fullerenol at the ﬁnal concentration of 50–150 mg/L
in the dark for 3 and 48 h at 37 °C.
2.6. Measurement of hemolysis
The hemolysis of erythrocytes was determined spectrophotomet-
rically at 523 nm based on the ratio of hemoglobin (Hb) released
from cells to the total cellular Hb content after hemolysis with dis-
tilled water. The ratio of hemolysis was calculated from the equation:
H %ð Þ ¼ A1
A2
⋅100%
whereH (%) is the per cent of hemolysis of the erythrocytes,A1 is the ab-
sorbance of the supernatants of the samples of the erythrocytes incu-
bated with or without fullerenol and A2 is the absorbance of the
supernatant of the samples of the erythrocytes incubated with or with-
out fullerenol after complete hemolysis with distilled water (100%).
2.7. Potassium efﬂux
The erythrocyte suspensions were centrifuged at 650 ×g for 10 min.
The resulting supernatant was assayed for its potassium content. The
concentration of potassium was measured by ﬂame atomic emission
spectrometry using a SpectrAA-300 apparatus (Varian, Australia).
2.8. Flow cytometry
Red blood cell suspensions after incubation were diluted to suspen-
sions containing approximately 106 cells/mL and analyzed using a
Becton–Dickinson, LSR II ﬂow cytometer, with simultaneous separate
detection at low angle (FSC) and right angle (SSC). The light scattered
near the forward direction (low angle) is expected to be proportional
to the size (volume) of the particle and is independent of the cell refrac-
tive index and shape, whereas scattering at the right angle depends on
the cell shape and internal properties of the scattering particles [29].
FSC/SSC is a dual parameter contour plot histogram proportional to
total cell diversity. Each measurement was done for 30,000 cells. Data
were analyzed with FlowJo software 7.2.2. (Tree Star Inc., USA).
2.9. Phase contrast microscopy
Erythrocytes incubated with or without fullerenol were observed
using a phase contrast microscope (Eclipse E600W Nikon, Japan) at
a magniﬁcation of 1000×.
2.10. Polyacrylamide gel electrophoresis (SDS-PAGE)
Erythrocyte membrane proteins were analyzed by SDS-PAGE as de-
scribed earlier [30]. Erythrocyte membranes were solubilized by addi-
tion of a solution containing: 10% SDS and 0.05% bromophenol blue in
0.25 M Tris–HCl buffer (pH 6.8) with or without 0.5 M dithiothreitol
(DTT). After incubation at 90 °C for 5 min, the samples containing
1 mg/mL of proteinwere subjected to one-dimensional SDS-PAGE. Elec-
trophoresis was carried out with 4% and 7.5% gels for condensation and
separation, respectively, in Tris–HCl buffer pH 8.8 containing 0.1% SDS.
Electrophoresis was carried out in a Bio-Rad system with a 20 mA cur-
rent. Protein bands were visualized by stainingwith Coomassie Brilliant
Blue R-250. The gels were digitalized and analyzed with the software
GelScan (KTE, Poland). The relative quantities of proteins in selected
bands were expressed as the percentage of the total protein quantity.
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
control 50 100 150
CK
+ 
[m
M]
Fullerenol concentration [mg/L] 
3 hours
48 hours
*
*
Fig. 2. The potassium leakage from erythrocytes incubated with fullerenol C60(OH)36,
at a concentration range of 0–150 mg/L for 3 and 48 h at 37 °C. Asterisks are used to
mark values that are statistically different in comparison with control values *p b 0.05.
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All experiments were run at least ﬁve times. Values were expressed
as themean ± standard deviation (SD) of at least ﬁve independent ex-
periments. For each experiment, blood samples (control and those incu-
batedwith chemical compounds)were taken from the same individual.
Datawere analyzed by one-way analysis of variance (ANOVA), followed
by Tukey's post-hoc test, all using the GraphPad 4.0 software.
3. Results and discussion
3.1. The inﬂuence of fullerenol on the level of hemolysis and the leakage
of potassium ions from erythrocytes
In order to estimate the inﬂuence of fullerenol on erythrocyte
membrane integrity, the cells were incubated with the compound in
the concentration range of 50–150 mg/L at 37 °C for 3 and 48 h. Sub-
sequently, the level of hemolysis and potassium ion leakage was in-
vestigated. The samples incubated with fullerenol for 3 h did not
show an increase in hemolysis or in release of potassium ions
(Figs. 1 and 2). Prolonged, 48-hour incubation caused signiﬁcant
autohemolysis and potassium ion leakage (Figs. 1 and 2). Fullerenol
present in the medium caused a slight, concentration-dependent de-
crease in hemolysis, which for the ﬁnal concentration of 150 mg/L
proved to be statistically signiﬁcant. The protective effect of fullerenol
in this case was estimated at 20.3%. Similar results were obtained for
the potassium ion leakage: for the ﬁnal concentration of 150 mg/L,
the amount of potassium released from the erythrocytes decreased
by 21.6% when compared to that from the control sample. This pro-
tective effect can be attributed to interactions between the hydroxyl
groups of fullerenols and the plasmamembranes, e.g., creating hydro-
gen bonds between the \OH groups of the nanocompound and plas-
ma membrane proteins or polar heads of membrane lipids [14,26,31].
In addition to hydrogen bonding, hydrophobic and electrostatic inter-
actions may also contribute to adsorption of fullerenol to the plasma
membrane [11]. Fullerenol has more than 30\OH groups on the sur-
face, which are responsible for the dipolar negative charge of this
molecule and is similar to the resultant charge of the erythrocyte
membranes. It can adsorb, however, to the protein domains of the
membrane by van der Waals or dipolar interactions [31]. These as-
sumptions are in agreement with data obtained via molecular model-
ing [25,32] as well as experimental data [26,33,34].
The leakage of potassium ions from the cells is related to disruption
of activemembrane transport and a result of the decrease in ATP levels,
which can occur during prolonged incubation of erythrocytes [35]. As
shown in our previous work, fullerenol inhibits the activity of
ion-dependent ATPases as a result of both direct interaction with the
enzyme and the inﬂuence of fullerenol on membrane ﬂuidity [26].0
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Fig. 1. The autohemolysis of erythrocytes incubated with fullerenol C60(OH)36, at a
concentration range of 0–150 mg/L for 3 and 48 h at 37 °C. Asterisks are used to
mark values that are statistically different in comparison with control values *p b 0.05.Inhibition of Na+,K+-ATPase in erythrocytes causes distortion of the
ion balance and leads to osmotic hemolysis [36,37].
Despite the inhibition of Na+,K+-ATPase by fullerenol, an increase in
hemolysis and potassium ion leakage was not observed. Blocking the
leakage can result from physical “blockages” of potassium channels by
fullerenol molecules. A similar effect was observed for blocking potassi-
um ion channels by fullerene and nanotubes, where the blockage effect
was dependent on the size and shape of the nanocompounds [38]. The
ion channels can beﬂanked by the nanocompounds as the result of elec-
trostatic interaction or plain adsorption, which inﬂuences ion exchange
and, therefore, cellular metabolism.
3.2. The inﬂuence of fullerenol on the content of cell membrane proteins
In order to investigate the inﬂuence of fullerenol on the membrane
proteins, erythrocyte ghosts incubated with fullerenol for 3 and 48 h at
37 °C were separated by SDS-PAGE electrophoresis in reductive and
non-reductive conditions. As presented in Fig. 3, fractions identiﬁed
after staining with Coomassie Brilliant Blue contained spectrins α and
β, ankyrin, band 3 (AE1), 4.1 (EPB41), 4.2 (EPB42) and 4.9 (EPB49) pro-
teins, actin, lowmolecular weight proteins and hemoglobin. The relative
contribution of each fraction expressed as the percentage of the total
amount of protein is shown in Table 1. There were no statistically signif-
icant differences between control samples and samples containingmem-
branes incubated with fullerenol up to 100 mg/L for 3 h. Interestingly,
for the samples containing 150 mg/L of fullerenol incubated in the
same conditions, there was a signiﬁcant decrease in the band identiﬁed
as actin with a simultaneous increase in the band 3 protein fraction.
The decline of the actin band when the highest concentration of
fullerenol was used can suggest that the nanocompound causes associa-
tion of this protein. The enrichment in the band3 protein fraction,which
has amolecularweight comparable to twomolecules of actin connected
by amolecule of fullerenol, suggests a possibility of interactions between
fullerenol and erythrocyte cytoskeletal proteins. A prolonged, 48-h incu-
bation resulted in the disappearance of the band 3 fraction and enrich-
ment in the broad band of low molecular mass proteins (smearing) in
control cells. This is a result of substantial fragmentation of band 3 pro-
tein, which could originate either from proteolytic or ROS-induced
cleavage [39]. The presence of fullerenol in all used concentrations
prevented the degradation of band 3 protein. The presented data indi-
cate that fullerenol preferentially binds to band 3 protein and prevents
its degradation. A large number of hydroxyl groups on the surface of
the fullerenol carbon cage provide possibilities for interaction and at-
tachment of othermolecules, e.g., drugs [40]. At the same time, function-
al \OH groups can adsorb to cytoskeletal erythrocyte proteins. These
properties of fullerenol can be used to improve utilization of erythro-
cytes as drug carriers. Prolonging the time of residence of a substance
(drug) in the circulation system is possible by attaching it to residues
protein aggregates 
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Fig. 3. SDS-PAGE of proteins of erythrocyte membranes incubated with fullerenol for 3 and 48 h at 37 °C under non-reductive or reductive conditions (DTT at 0.25 mM). Arrows
indicate a complete disappearance of the band 3 protein.
2010 J. Grebowski et al. / Biochimica et Biophysica Acta 1828 (2013) 2007–2014of the erythrocyte membrane, such as band 3 protein or glycophorin.
This method has been described by Krantz [41], and it is based on the
use of “anchors” —moleculeswith functional groupswith strong afﬁnity
for erythrocyte cytoskeletal proteins. As fullerenol is covered with polar
\OH groups, it is well suited to function as an “anchor”.
The band 3 protein is an ion exchanger with a fundamental role in
maintaining the oxygen transport function of red blood cells and acts
as an anchor for a series of key glycolytic enzymes and spectrin. The
membrane alterations related to prolonged incubation cause the
echinocyte or spheroechinocyte phenotypes. Finally, the cell activates
a process of vesiculation, in order to eliminate proteins and lipids that
have been altered by oxidative stress to protect the cell from a further
chain reaction of stress and consequent removal from the circulation.
Changes in band 3 protein trigger signals at themembrane to “remove”
the cell, through IgG- or complement-mediated phagocytosis by the
recipients' Kupffer cells [42].
In whole erythrocytes, fullerenol, by adsorption to band 3 protein can
indirectly interact with cytoplasmic proteins. The results obtained with
the use of isolated erythrocyte ghosts are consistent with the inﬂuence
of fullerenol on peripheral and transmembrane proteins, such as ATPases
[26] and band 3 protein. The inﬂuence of fullerenol on transmembraneTable 1
Relative content of membrane proteins after SDS-PAGE of erythrocyte membranes incubat
under non-reductive or reductive conditions (DTT at 0.25 mM).
Fullerenol concentration
[mg/L]
3 h
Control membrane
proteins
50 100 150
Reductive conditions (DTT — 0.25 mM)
Protein aggregates 1.61 ± 0.64 1.67 ± 0.47 1.71 ± 0.56 1.64
Spectrin α 18.43 ± 2.96 18.54 ± 1.73 18.63 ± 0.58 18.67
Spectrin β 16.39 ± 2.61 16.23 ± 2.01 16.17 ± 2.46 16.84
Ankyrin 3.06 ± 1.02 3.39 ± 1.30 3.28 ± 1.19 2.82
Band 3 28.34 ± 1.70 30.59 ± 2.07 31.17 ± 1.34 32.43
Band 4.1 9.48 ± 1.26 9.29 ± 0.85 8.80 ± 0.59 8.52
Band 4.2 9.10 ± 1.05 7.58 ± 0.91 7.89 ± 0.50 7.03
Band 4.9 3.22 ± 0.06 3.36 ± 0.26 3.15 ± 0.17 3.04
Actin 8.89 ± 0.66 8.03 ± 0.87 8.24 ± 1.37 6.41
Small mass proteins 1.95 ± 0.27 1.93 ± 0.31 1.65 ± 0.23 1.78
Non-reductive conditions
Protein aggregates 2.54 ± 0.84 2.91 ± 0.80 3.21 ± 1.00 3.42
Spectrin α 19.22 ± 2.99 18.12 ± 1.64 18.73 ± 1.89 20.16
Spectrin β 15.98 ± 1.57 18.35 ± 4.39 17.13 ± 3.34 16.84
Ankyrin 3.91 ± 0.64 3.67 ± 1.33 3.67 ± 1.18 3.47
Band 3 28.39 ± 0.68 28.92 ± 0.94 29.11 ± 1.56 30.38
Band 4.1 8.47 ± 1.06 9.30 ± 0.61 8.89 ± 0.65 8.87
Band 4.2 8.01 ± 1.30 7.13 ± 0.96 6.91 ± 0.39 6.80
Band 4.9 3.27 ± 0.91 1.99 ± 1.45 3.39 ± 0.04 3.38
Actin 9.74 ± 0.46 7.20 ± 1.80 7.40 ± 1.16 5.84
Small mass proteins 1.98 ± 0.55 2.01 ± 0.39 2.24 ± 0.55 2.23
Asterisks are used to mark values that are statistically different in comparison to control vaproteins is clearly reﬂected by the changes in activity of Na+/K+-ATPase,
Ca2+-ATPase andMg2+-ATPase, which can originate from both direct in-
teraction with the proteins and indirect inﬂuence on the ﬂuidity of the
membrane [26]. Band3protein plays a central role in cytoskeleton forma-
tion, therefore, conformational changes induced by various factors in this
molecule result in echinocyte formation [43]. Themorphological changes
of erythrocytes induced by fullerenol were investigatedwith ﬂow cytom-
etry and phase contrast microscopy and are described in Section 3.3.
It has to be noted that a 48-h incubation of erythrocytes led to aggre-
gation of the membrane proteins. The use of reducing agents prevents
these events, indicating that aggregation is promoted by the creation
of\S\S\ bridges [30]. Fullerenol, when used in concentrations up to
100 mg/L did not inﬂuence aggregate formation. An increase in concen-
tration to 150 mg/L, however, promoted protein aggregation. Aggre-
gates formed in the presence of fullerenol in these conditions could
not be reduced by DDT, which conﬁrms fullerenol–protein association.
The inﬂuence of fullerenol on the proteins is not limited to associa-
tion or networking. This nanocompound can induce deformation of
the protein in the binding residues. Low concentrations of C60(OH)20
(15–30 mg/L) inhibit microtubule polymerization by binding to tubulin
in the ratio 9:1 [44]. Fullerenol C60(OH)36, by association with band 3ed with fullerenol at the concentration range of 50–150 mg/L for 3 and 48 h at 37 °C
48 h
Control membrane
proteins
50 100 150
± 0.51 2.20 ± 0.80 3.91 ± 1.29 4.38 ± 2.00 4.91 ± 1.52*
± 1.52 11.50 ± 1.24 12.58 ± 2.07 12.72 ± 1.35 12.33 ± 1.11
± 1.97 16.60 ± 1.63 17.17 ± 1.20 15.79 ± 3.58 15.11 ± 1.03
± 0.98 3.97 ± 1.13 4.79 ± 1.07 4.96 ± 1.58 4.73 ± 1.05
± 1.08* 3.50 ± 7.00 27.87 ± 2.09* 31.07 ± 1.56* 32.34 ± 2.91*
± 0.45 11.78 ± 1.57 10.63 ± 2.47 8.82 ± 0.64* 8.34 ± 1.60*
± 0.65 10.37 ± 2.25 8.74 ± 1.63 8.76 ± 1.37 9.61 ± 4.34
± 0.25 4.50 ± 4.27 3.67 ± 3.22 3.69 ± 3.24 3.52 ± 3.06
± 0.50* 11.46 ± 1.28 7.54 ± 1.10* 6.14 ± 1.78* 5.22 ± 1.34*
± 0.42 5.22 ± 0.40 3.88 ± 0.54* 3.53 ± 0.84* 3.51 ± 0.85*
± 0.67 3.62 ± 0.54 4.87 ± 0.88 4.81 ± 0.96 5.40 ± 1.01*
± 1.94 13.81 ± 0.24 12.41 ± 1.10 12.79 ± 1.05 13.39 ± 3.13
± 2.70 16.88 ± 1.53 13.91 ± 1.67* 12.35 ± 1.98* 11.36 ± 1.11*
± 1.15 4.15 ± 0.89 4.57 ± 1.12 4.18 ± 1.14 3.79 ± 0.85
± 1.06* 3.54 ± 6.12 27.43 ± 2.40* 27.28 ± 3.67* 26.49 ± 2.76*
± 0.54 12.11 ± 2.66 7.18 ± 0.51* 6.76 ± 0.68* 6.34 ± 0.90*
± 0.71 9.06 ± 2.11 5.53 ± 0.59* 4.85 ± 0.70* 4.06 ± 0.33*
± 0.20 5.55 ± 1.56 4.90 ± 0.73 5.59 ± 1.03 3.81 ± 0.53
± 0.75* 8.09 ± 1.17 3.40 ± 0.42* 2.77 ± 0.39* 2.52 ± 0.36*
± 0.49 6.81 ± 1.92 2.83 ± 0.60* 2.45 ± 0.50* 2.15 ± 0.44*
lues *p b 0.05.
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binding sites of spectrin, band 4.1 and 4.2 proteins or actin, leading to
changes in the cytoskeleton affecting erythrocyte morphology [45–47].
3.3. Changes in shape of the erythrocytes analyzed by ﬂow cytometry and
phase contrast microscopy
The changes in erythrocyte size and shape were assessed on the
basis of microphotography and light dispersion parameters FSC-A
and SSC-A obtained by ﬂow cytometry. Utilization of ﬂow cytometry
provides a fast and very precise estimation of the physico-chemical
and biological properties of cells [21,48,49]. Fig. 4 shows the diagrams
and histograms obtained for erythrocytes incubated in the presence3 h
48 h
control 50 mg/L
FSC
SSC
A
B
control 50 mg/L
48 h
Fig. 4. Flow cytometry analysis of fullerenol-induced changes in RBC morphology. (A) Scatte
with fullerenol in concentrations ranging from 50 to 150 mg/L. The FSC-A/SSC-A diagram
histograms represent the light scattered near the forward direction (proportional to the vol
pendent on cell shape and internal properties).and absence of C60(OH)36 for 3 and 48 h in accordance to the frontal
(FSC) and lateral (SSC) light dispersion.
After a 48-h incubation in all investigated samples, a fraction of cells
with an increased FSC parameter was detected (Fig. 4A). This effect,
however, cannot be attributed to the presence of fullerenol, as control
cells displayed the same features and no concentration-dependence
was observed. Prolonged incubations of erythrocytes led to exhaustion
of cellular reductive components and structural and functional changes
in the membranes: degradation of phosphatidylserine [50] and sialic
acid, which are the main components establishing the negative charge
on the outer side of the membrane [51]. All these effects can be a direct
result of prolonged incubation at 37 °C and cause signiﬁcant changes in
morphology and size of the erythrocytes.100 mg/L 150 mg/L
100 mg/L 150 mg/L
ring diagrams of human control erythrocytes and erythrocytes incubated for 3 and 48 h
is a dual parameter contour plot proportional to the total cell diversity. (B) The FSC-A
ume of the particles). The SSC-A histograms represent scattering at the right angle (de-
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Fig. 5. Flow cytometry analysis of the shape of control erythrocytes and erythrocytes
incubated with fullerenol in the concentrations ranging from 50 to 150 mg/L. (*)
Signiﬁcantly different from control (p b 0.05); one-way ANOVA and a posteriori
Tukey's test.
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structure of the outer cellular membrane. After analyzing the percent-
age of unaffected cells it was apparent that this parameter was slight-
ly less in the samples treated with fullerenol at the concentration of
150 mg/L for 3 h (Fig. 5). The changes become enhanced with an in-
creased incubation time and fullerenol concentration (Fig. 4B), to
reach 15% of morphologically changed cells in comparison to the con-
trol when incubated with 150 mg/L for 48 h.
Changes in the shape of the cells observed by using ﬂow cytome-
try are in accordance with microscopic observations of erythrocytes
exposed to fullerenol. Fig. 6 shows the light microscopic images of
erythrocytes incubated with different concentrations of fullerenol
(1000× magniﬁed). Non-treated cells after a 3-h incubation at 37 °C
have the characteristic shape of discocites. In the samples incubated
in the same conditions with 150 mg/L fullerenol, slight changes
were observed, including the formation of dendrites, which are typi-
cal for echinocyte forms. After a 48-h incubation, a substantial num-
ber of control cells showed signs of echinocytic transformation and
aggregation. Fullerenol seemed to slightly enhance this effect at a
concentration of 150 mg/L. These results are consistent with previous
data obtained via ﬂow cytometry. Formation of echinocytes is caused
by a number of factors, which, among other things, affect the confor-
mation of band 3 protein, the main foundation of the cytoskeleton
[43]. Moreover, it is a transmembrane anion exchanger protein3 h
48 h
control 50 mg/L
10 µm
Fig. 6.Microscopic images of erythrocytes exposed to fullerenol. The cells were incubated in
for 150 mg/L of C60(OH)36 — indicated by arrows. All images are at the same scale (scale bresponsible for chloride and bicarbonate transport, which is correlat-
ed with potassium and sodium active transport by Na+/K+-ATPase.
Fullerenol, by inhibiting the function of Mg2+-dependent membrane
ATPases [26], may be able to disturb the distribution of lipids in the
inner and outer membrane layers, thus, triggering the collapse of
the discoidal shape of erythrocytes [52]. Further, the alteredmorphol-
ogy of the cells can be explained by the formation of hydrogen bonds
between the nanoparticles and the lipid head groups. The presence of
each nanoparticle engaged a number of lipids to reduce their areas
per lipid molecule. It is not impossible that a synergistic effect of
fullerenol on membrane ATPases, band 3 protein and lipids is respon-
sible for part of the echinocytic transformation.
Our data show that fullerenol can slightly alter the morphology
and, therefore, the inner-organization of the cells through association
with cytoskeletal proteins. These results conﬁrm that fullerenol is
able to interact with transmembrane cytoskeletal proteins, in partic-
ular band 3 protein and ATPases.4. Conclusion
The presented data are promising in the context of utilizing fullerenol
as a drug carrier. The interaction between band 3 protein and hydroxyl
groups of the compound creates a possibility to use fullerenol as an
“anchor” between erythrocyte and an anti-cancer drug.
We can assume that interactions will be limited to those with sur-
face and transmembrane proteins, such as ATPases [26] and band 3
protein. The inhibition of potassium ion leaks and subsequent
changes in membrane electrostatic charge combined with interac-
tions with band 3 proteins can eventually lead to changes in erythro-
cyte epitopes. Such changes can result in increased capture by the RES
and targeting to speciﬁc organs (liver, spleen or bonemarrow), which
can be an advantage in light of the targeted therapies. Moreover, the
data presented in this study show that changes in the morphology of
erythrocytes triggered by interaction with fullerenol in high concen-
trations (up to 150 mg/L) do not lead to an increase in hemolysis or
potassium ion leakage, but even prevent them in a moderate manner.
In conclusion, fullerenol in the range of concentrations between
50 and 150 mg/L does not show signiﬁcant toxic effects in erythro-
cytes. Fig. 7 shows a proposed mechanism of interaction between
fullerenol and cytoskeletal proteins. These results reveal the need of
further investigation into the interactions between biological mem-
branes and soluble fullerene derivatives in order to verify their toxic-
ity and possibilities of utilization as drug carriers in more detail.100 mg/L 150 mg/L
the presence of fullerenol at 50–150 mg/L for 3 and 48 h at 37 °C. Echinocyte formation
ar: 10 μm).
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Fig. 7. Fullerenol interactions with the band 3 protein and the location of fullerenol in the lipid bilayer. Fullerenol C60(OH)36, by associating with band 3 protein, does not only pre-
vent its degradation, but can also inﬂuence the binding sites of spectrin, band 4.1 and 4.2 proteins or actin, leading to changes in the cytoskeleton affecting erythrocyte morphology.
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